| Kim Ahearn, RPH | |
|
209 Route 101, Bedford, NH 03110-5441 | |
| (603) 472-3919 | |
| (603) 472-7448 |
| Full Name | Kim Ahearn |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 209 Route 101, Bedford, New Hampshire |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013455872 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2826 (New Hampshire) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Kim Ahearn, RPH 209 Route 101, Bedford, NH 03110-5441 Ph: (603) 472-3919 | Kim Ahearn, RPH 209 Route 101, Bedford, NH 03110-5441 Ph: (603) 472-3919 |
News Archive
CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases.
[A]ll of these last-minute policy shifts confuse people who were already struggling to understand a complex new system, ... The cumulative effect is that at least some people -; we hope not many -; will misunderstand their responsibilities under the law or be deterred from seeking coverage. The biggest danger is that the Obama administration is encouraging politicians to meddle in the health-care system every time a few vocal constituents get upset about its requirements (12/21).
The immunologically relevant MHC class II molecules are ubiquitously found in many animal species, which is why the discovery will play an important role in assessing the risk of spill-over infections to other species than bats.
Cara Therapeutics, Inc. today announced positive results from a Phase II study for the treatment of acute post-operative pain with its novel, peptide-based, peripherally-acting kappa opioid agonist, CR845.
VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 agonists for the treatment of cancer, respiratory and autoimmune diseases, today announced the presentation of results from a Phase 1 clinical trial of VTX-2337, a selective TLR8 agonist in patients with advanced solid tumors. Data were presented at the American Society of Clinical Oncology Annual Meeting in Chicago, IL.
› Verified 9 days ago
Dr. Falon Anne Kaspszak, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 209 Route 101, Bedford, NH 03110 Phone: 603-472-3919 Fax: 603-472-7448 | |
Laurie Keith, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 258 Wallace Rd, Bedford, NH 03110 Phone: 603-472-5847 | |
Nicholas Driscoll, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 258 Wallace Rd, Bedford, NH 03110 Phone: 603-472-5847 | |
Mrs. Ronda Lee Hatin, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 5 Colby Ct, Bedford, NH 03110 Phone: 603-622-2320 | |
Mrs. Lori Ellen Connors, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 220 S River Rd, Bedford, NH 03110 Phone: 603-263-0062 | |
Ms. Narmin Pirmohamed, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 8 Technology Dr, Bedford, NH 03110 Phone: 603-626-6200 |